Valproate-Induced Encephalopathy in Three Cases

被引:0
|
作者
Polat, Fatma [1 ]
Koskderelioglu, Asli [1 ]
Alpaydin, Sezin [1 ]
Keskinoz, Nesli [2 ]
Arac, Nilgun [1 ]
Gonul, Ali Saffet [2 ]
Kocaman, Ayse [1 ]
Sirin, Hadiye [1 ]
机构
[1] Univ Ege, Fac Med, Dept Neurol, TR-35100 Izmir, Turkey
[2] Univ Ege, Fac Med, Dept Psychiat, Izmir, Turkey
关键词
Valproic acid; adverse effects; encephalopathy;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Valproic acid-induced encephalopathy is a serious complication of valproate, rarely observed, and can lead to death if early diagnosis is not made. It is clinically presented as mental status changes that range from drowsiness to lethargy and coma, focal or bilateral neurological deficits, seizure, vomiting, and marked electroencephalography (EEG) background slowing, with or without hyperammonemia. It can also be properly managed by discontinuation of the drug. We present three cases who developed vomiting, disturbance in consciousness, EEG-slowing, and elevated serum ammonia levels. In all cases, symptoms resolved after termination of valproate. Most notably, these side effects occurred in the presence of normal liver enzymes and normal valproate concentrations. Development of unconsciousness and associated EEG slow waves are observed rarely in VPA-induced encephalopathy, and this is discussed together with a review of the literature. Serum ammonia level is an important parameter in the early diagnosis of this rare adverse event. The clinical symptomatology and EEG findings have significant importance in the differential diagnosis when encephalopathy occurs without hyperammonemia and with normal or slight increase in serum ammonia level.
引用
收藏
页码:203 / 207
页数:5
相关论文
共 50 条
  • [41] Fulminant progression of demyelinating disease after valproate-induced encephalopathy
    Blindauer, KA
    Harrington, G
    Morris, GL
    Ho, KC
    NEUROLOGY, 1998, 51 (01) : 292 - 295
  • [42] Non-hyperammonaemia valproate-induced encephalopathy: A case report
    Chen, Ling
    Xu, Zucai
    Huang, Hao
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (03) : 415 - 419
  • [43] Valproate-induced encephalopathy: A depiction of symptoms on the basis of a case report
    Goepfert, C
    Ostermeier, CP
    Haen, E
    PHARMACOPSYCHIATRY, 2005, 38 (01) : 50 - 51
  • [44] Valproate-induced hyperammonemic encephalopathy in a neonate: Treatment with carglumic acid
    Fernandez Colomer, B.
    Rekarte Garcia, S.
    Garcia Lopez, J. E.
    Perez Gonzalez, C.
    Montes Granda, M.
    Coto Cotallo, G. D.
    ANALES DE PEDIATRIA, 2014, 81 (04): : 251 - 255
  • [45] A valproate-induced encephalopathy without hyperammonemia but with triphasic waves and myoclonus
    Bilen, N. Keskinoz
    Polat, F.
    Gonul, A. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S578 - S578
  • [46] Valproate-induced hyperammonemia in the psychiatric setting: 2 cases
    Panikkar, GP
    Gilman, SM
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (08) : 557 - 559
  • [47] Valproate-induced panhypogammaglobulinemia
    Eom, Tae-Hoon
    Lee, Hyun-Seung
    Jang, Pil-Sang
    Kim, Young-Hoon
    NEUROLOGICAL SCIENCES, 2013, 34 (06) : 1003 - 1004
  • [48] Valproate-induced hyperammonaemia
    Raja, M
    Azzoni, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (06) : 631 - 633
  • [49] Valproate-Induced Nonhyperammonemic Encephalopathy with Electroencephalogram Background Slowing and Triphasic Waves
    Dericioglu, Nese
    Cakan, Melike
    NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, 2023, 40 (03): : 176 - 178
  • [50] Reversible valproate-induced subacute encephalopathy caused by a mitochondrial DNA variant
    De Michele, G.
    Sorrentino, P.
    Ruggiero, L.
    De Michele, G.
    Peluso, S.
    Antenora, A.
    Nesti, C.
    Santorelli, F. M.
    Filla, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 696 - 697